11:13 AM EST, 11/10/2025 (MT Newswires) -- Lyell Immunopharma ( LYEL ) said Monday it acquired exclusive global rights to LYL273, a CAR T-cell product candidate for metastatic colorectal cancer, from Innovative Cellular Therapeutics.

The deal includes an upfront payment of $40 million, 1.9 million Lyell shares, and up to $820 million in milestone payments, Lyell said.

LYL273 showed a 67% overall response rate and 83% disease control rate in a US Phase 1 trial, Lyell said, adding that the next data update is expected in the first half of 2026.

Lyell said it anticipates the deal to have a "modest" impact on 2025 expenses and also expects to have sufficient cash to fund operations into 2027 following the close of the transaction, which excludes mainland China, Hong Kong, Macau and Taiwan.

Price: 17.52, Change: +0.01, Percent Change: +0.06